Kling reports on advancing pipeline of therapeutic antibodies targeting novel antigens discovered with its best-in-class B-cell screening platform, Kling-Select Progress on in vitro and in vivo validation of two highly specific tumor antigens is reported: CD43s, a sialylated-glyco…